Comparative Pharmacology
Head-to-head clinical analysis: LORATADINE REDIDOSE versus TELDRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LORATADINE REDIDOSE versus TELDRIN.
LORATADINE REDIDOSE vs TELDRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective peripheral H1 receptor antagonist; inhibits histamine release from mast cells.
TELDRIN contains loratadine and pseudoephedrine. Loratadine is a long-acting tricyclic antihistamine with selective peripheral H1-receptor antagonism. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction.
10 mg orally once daily
1-2 mg orally twice daily; maximum 4 mg/day.
None Documented
None Documented
Terminal elimination half-life is 8–14 hours (mean ~12 hours) for desloratadine (active metabolite); parent loratadine half-life ~3–20 hours (mean ~8 hours). Clinically, once-daily dosing maintains steady state in 5–7 days.
Terminal half-life: 9-12 hours (range 8-14) in healthy adults; prolonged in renal impairment.
Renal (approximately 40% as metabolites), biliary/fecal (approximately 60% as metabolites). Less than 1% excreted unchanged in urine.
Renal: 55-60% unchanged; fecal: 35-40%; minor biliary elimination.
Category A/B
Category C
Antihistamine
Antihistamine